In the United States, some Hispanic or Latino patients have increased risk of asthma attacks and asthma -related hospitalization. According to the results of the study released at the 2022 Annual Science Conference of the American Society of Allergy, Asthma and Immunology (ACAAI) in Louisville, Kentucky, patients who had severe, uncontrollable asthma in two clinical trials had worsened and hospitalized rates in year 1 than those who received placebo. The two trials of
were from the Phase 2b PATHWAY (NCT02054130) and the Phase 3 NAVIGATOR study (NCT03347279). The researchers conducted an after-hoc analysis of their aggregated data to evaluate the efficacy of tezepelumab in patients with severe, uncontrolled asthma in Hispanic or Latino.
These two multicenter, randomized, placebo-controlled PATHWAY and NAVIGATOR trials had similar designs, with the included patients aged 12 to 80 years old, who received tezepelumab 210 mg or placebo subcutaneous injection every 4 weeks for up to 52 weeks. The researchers evaluated the annualized rate of asthma worsening (AAER) and the annualized rate of asthma worsening that requires hospitalization for more than 52 weeks.
Among the 1334 patients in 2 trials, 166 claimed to be Hispanic or Latino, of which 45% were from Argentina, 27% were from the United States and 24% were from Brazil.
At the beginning, the percentage of forced exhalation volume before bronchodilator was predicted in 1 second (67.5% and 61.3% respectively) in Hispanic/Latino patients compared with non-Hispanic/Latino patients.
In addition, more Hispanic/Latino patients experienced perennial allergies (77.1% and 58.8%, respectively), and fewer Hispanic/Latino patients received maintenance oral corticosteroids (2.4% and 10.1%, respectively).
When using placebo, the AAER score of 1.67 for Hispanic/Latino patients and 1.11 when using tezepelumab, a 34% decrease compared to placebo. The annualized rate of asthma worsening in Hispanic/Latino subjects requiring hospitalization was 0.12 and 0.00 with tezepelumab, a 100% decrease compared to placebo.
The study authors said: "In Hispanic or Latino patients with severe, uncontrolled asthma, the rate of deterioration among tezepelumab recipients was lower in 52 weeks, including those requiring hospitalization."
Reference source: Hill J, Carr T, Ambrose C et al. ‘Efficacy of tezepelumab in Hispanic or Latino patients with severe, uncontrolled asthma’. Published in Ann Allergy Asthma Immunol. 2022;125(5):S35-S36. doi:10.1016/j.anai.2022.08.606
Note: This article aims to introduce medical and health research, and does not provide any basis for medication use. For specific medication use guidelines, please consult the attending physician.
